TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy

被引：7

作者：

Alberto Henriquez-Hernandez, Luis ^{[1
]}

Fernandez Perez, Leandro ^{[1
]}

Gonzalez Hernandez, Ana ^{[2
]}

Cabrera de Leon, Antonio ^{[2
]}

Diaz-Chico, Bonifacio ^{[3
]}

Murias Rosales, A. ^{[4
]}

机构：

[1] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria 35016, Spain

[2] Hosp Univ La Candelaria, Hosp La Candelaria, Res Unit, Santa Cruz de Tenerife 38010, Spain

[3] Univ Las Palmas Gran Canaria, Physiol Biochem & Mol Biol Dept, Las Palmas Gran Canaria 35016, Spain

[4] Hosp Univ Insular Gran Canaria, Med Oncol Serv, Las Palmas Gran Canaria 35016, Spain

来源：

CANCER EPIDEMIOLOGY | 2010年 / 34卷 / 04期

关键词：

Breast cancer; Adjuvant chemotherapy; Multifocal tumour; Polymorphism; PCR-RFLP; Risk factors; MTHFR; THYMIDYLATE SYNTHASE GENE; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK; FOLATE; DISEASE; METABOLISM; EXPRESSION; GENOTYPE; C3435T; DIET;

D O I：

10.1016/j.canep.2010.03.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose. The distribution of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms was investigated in 80 consecutive breast cancer patients treated with adjuvant chemotherapy Results Observed allelic frequencies were TSER, (2)0 55 and (3)0 45, MTHFR C677T, (C) 065 and (T) 035: p53 Arg72Pro, (Arg) 076 and (Pro) 024, MDR1 C3435T, (C) 051 and (T) 0.49 MTHFR C677T was found to be a strong predictor of the presence of multifocal tumour (odds ratio, 4 1, 95% CI, 1 1-15 7, P = 0 035) Conclusion Our data indicate that breast cancer patients with the C/C variant may Present multifocal tumour most frequently (C) 2010 Elsevier Ltd All rights reserved

引用

下载

页码：490 / 493

页数：4

共 50 条

[21] P53 gene polymorphisms and breast cancer risk in Arab women
Shafika Alawadi
Lina Ghabreau
Mervat Alsaleh
Zainab Abdulaziz
Mohamed Rafeek
Nizar Akil
Moussa Alkhalaf
Medical Oncology, 2011, 28 : 709 - 715
[22] p53 polymorphisms and haplotypes in breast cancer
Sjalander, A
Birgander, R
Hallmans, G
Cajander, S
Lenner, P
Athlin, L
Beckman, G
Beckman, L
CARCINOGENESIS, 1996, 17 (06) : 1313 - 1316
[23] The inactivation of p53 can lead to the hyperexpression of the MDR1 gene and to chemoresistance in certain cancers
Benard, J
BULLETIN DU CANCER, 1997, 84 (11) : 1085 - 1085
[24] TRANSACTIVATION OF THE HUMAN MULTIDRUG-RESISTANCE (MDR1) GENE PROMOTER BY P53 MUTANTS
NGUYEN, KT
LIU, BR
UEDA, K
GOTTESMAN, MM
PASTAN, I
CHIN, KV
ONCOLOGY RESEARCH, 1994, 6 (02) : 71 - 77
[25] MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients
Illmer, T
Schuler, US
Thiede, C
Schwarz, UI
Kim, RB
Gotthard, S
Freund, D
Schäkel, U
Ehninger, G
Schaich, M
CANCER RESEARCH, 2002, 62 (17) : 4955 - 4962
[26] Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients
Askmalm, MS
Carstensen, J
Nordenskjöld, B
Olsson, B
Rutqvist, LE
Skoog, L
Stål, O
ACTA ONCOLOGICA, 2004, 43 (03) : 235 - 244
[27] ROLE OF MDR1 AND P53 EXPRESSION IN THE CHEMORESISTANCE OF LUNG CARCINOMAS
PEOCH, M
BRAMBILLA, E
MORO, D
GAZZERI, S
BRAMBILLA, C
BULLETIN DU CANCER, 1994, 81 : S98 - S104
[28] Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer
Akkiprik, Mustafa
Sonmez, Ozgur
Gulluoglu, Bahadir M.
Caglar, Hale B.
Kaya, Handan
Demirkalem, Pakize
Abacioglu, Ufuk
Sengoz, Meric
Sav, Aydin
Ozer, Ayse
PATHOLOGY & ONCOLOGY RESEARCH, 2009, 15 (03) : 359 - 368
[29] Is p53 a breast cancer gene?
Polyak, K
CANCER BIOLOGY & THERAPY, 2002, 1 (01) : 37 - 38
[30] Analysis of MDR1 polymorphisms according to doxorubicin and docetaxel pharmacokinetics in patients with breast cancer
Gligorov, Joseph
Selle, Frederic
Beerblock, Karine
Saintigny, Pierre
Avenin, Daniele
Lotz, Jean-Pierre
Rezai, Keyvan
Bernaudin, Jean-Francois
Uzan, Serge
Levy, Pierre
Lokiec, Francois
Fajac, Anne
CANCER RESEARCH, 2006, 66 (08)

← 1 2 3 4 5 →